173 related articles for article (PubMed ID: 30031101)
41. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
[TBL] [Abstract][Full Text] [Related]
42. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience.
Wong J; Koch AL; Deneve JL; Fulp W; Tanvetyanon T; Dessureault S
Ann Surg Oncol; 2014 May; 21(5):1480-6. PubMed ID: 24158467
[TBL] [Abstract][Full Text] [Related]
43. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center.
Aydin N; Sardi A; Milovanov V; Nieroda C; Sittig M; Nunez MF; Jimenez W; Gushchin V
Am Surg; 2015 Dec; 81(12):1253-9. PubMed ID: 26736164
[TBL] [Abstract][Full Text] [Related]
44. IMP3 Predicts Invasion and Prognosis in Human Lung Adenocarcinoma.
Yan J; Wei Q; Jian W; Qiu B; Wen J; Liu J; Fu B; Zhou X; Zhao T
Lung; 2016 Feb; 194(1):137-46. PubMed ID: 26608347
[TBL] [Abstract][Full Text] [Related]
45. Malignant Peritoneal Mesothelioma: Treatment Options and Survival.
Salo SAS; Ilonen I; Laaksonen S; Myllärniemi M; Salo JA; Rantanen T
Anticancer Res; 2019 Feb; 39(2):839-845. PubMed ID: 30711965
[TBL] [Abstract][Full Text] [Related]
46. Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.
Kaya H; Sezgı C; Tanrıkulu AC; Taylan M; Abakay O; Sen HS; Abakay A; Kucukoner M; Kapan M
Neoplasma; 2014; 61(4):433-8. PubMed ID: 24645844
[TBL] [Abstract][Full Text] [Related]
47. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
[TBL] [Abstract][Full Text] [Related]
48. The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma.
Chou A; Toon CW; Clarkson A; Sheen A; Sioson L; Gill AJ
Histopathology; 2018 Feb; 72(3):509-515. PubMed ID: 28889523
[TBL] [Abstract][Full Text] [Related]
49. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
Marchevsky AM; LeStang N; Hiroshima K; Pelosi G; Attanoos R; Churg A; Chirieac L; Dacic S; Husain A; Khoor A; Klebe S; Lantuejoul S; Roggli V; Vignaud JM; Weynard B; Sauter J; Henderson D; Nabeshima K; Galateau-Salle F
Hum Pathol; 2017 Sep; 67():160-168. PubMed ID: 28782639
[TBL] [Abstract][Full Text] [Related]
50. Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.
Otoshi T; Kataoka Y; Kaku S; Iki R; Hirabayashi M
In Vivo; 2018; 32(2):445-450. PubMed ID: 29475935
[TBL] [Abstract][Full Text] [Related]
51. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies.
Polanco PM; Ding Y; Knox JM; Ramalingam L; Jones H; Hogg ME; Zureikat AH; Holtzman MP; Pingpank J; Ahrendt S; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2015 May; 22(5):1673-9. PubMed ID: 25377640
[TBL] [Abstract][Full Text] [Related]
52. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
[TBL] [Abstract][Full Text] [Related]
53. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
54. CD146 and insulin-like growth factor 2 mRNA-binding protein 3 predict prognosis of asbestos-induced rat mesothelioma.
Okazaki Y; Nagai H; Chew SH; Li J; Funahashi S; Tsujimura T; Toyokuni S
Cancer Sci; 2013 Aug; 104(8):989-95. PubMed ID: 23621518
[TBL] [Abstract][Full Text] [Related]
55. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
Ihemelandu C; Bijelic L; Sugarbaker PH
Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
[TBL] [Abstract][Full Text] [Related]
56. Synchronous pleural and peritoneal malignant mesothelioma: a case report and review of literature.
Del Gobbo A; Fiori S; Gaudioso G; Bonaparte E; Tabano S; Palleschi A; Bosari S; Ferrero S
Int J Clin Exp Pathol; 2014; 7(5):2484-9. PubMed ID: 24966960
[TBL] [Abstract][Full Text] [Related]
57. MUC1 has prognostic significance in malignant peritoneal mesothelioma.
Pillai K; Pourgholami MH; Chua TC; Morris DL
Int J Biol Markers; 2013 Sep; 28(3):303-12. PubMed ID: 23828409
[TBL] [Abstract][Full Text] [Related]
58. Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy.
Lee M; Alexander HR; Burke A
Pathology; 2013 Aug; 45(5):464-73. PubMed ID: 23846294
[TBL] [Abstract][Full Text] [Related]
59. Insulin-like growth factor II messenger RNA-binding protein 3 expression in gastrointestinal mesenchymal tumors.
Yamamoto H; Arakaki K; Morimatsu K; Zaitsu Y; Fujita A; Kohashi K; Hirahashi M; Motoshita J; Oshiro Y; Oda Y
Hum Pathol; 2014 Mar; 45(3):481-7. PubMed ID: 24411949
[TBL] [Abstract][Full Text] [Related]
60. IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence.
Massironi S; Del Gobbo A; Cavalcoli F; Fiori S; Conte D; Pellegrinelli A; Milione M; Ferrero S
Endocrine; 2017 Nov; 58(2):360-367. PubMed ID: 28210937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
